Finance

Beta
Lists
CYTK:NASDAQ
Cytokinetics, Inc.
US$80,80
0,00%
(0,00) 1D
US$80,70
-0,12% (-0,10)
Pre-market
Closed: 25 ມິ.ຖ., 16 ໂມງ 0 ນາທີ 01 ວິນາທີ GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CYTK...
Mkt. cap
໑໐,໙໕ ຕື້
Avg. vol.
໒,໐໔ ລ້ານ
Volume
໙໐໖,໐໐
52-wk high
US$82,83
52-wk low
US$32,66
EPS
US$-6,84
Beta
໐,໔໒
Shares outstanding
໑໒໔,໔໓ ລ້ານ
No. of employees
໖໗໓
Mkt. cap
໑໐,໙໕ ຕື້
Avg. vol.
໒,໐໔ ລ້ານ
Volume
໙໐໖,໐໐
52-wk high
US$82,83
52-wk low
US$32,66
EPS
US$-6,84
Beta
໐,໔໒
Shares outstanding
໑໒໔,໔໓ ລ້ານ
No. of employees
໖໗໓
News stories
From sources across the web
Investing.com Canada
Investing.com Canada
·
1 ມື້ກ່ອນ
Form 144 CYTOKINETICS For: 24 June By Investing.com
Investing.com Canada
Investing.com Canada
·
2 ມື້ກ່ອນ
Form 4 Cytokinetics Inc For: 23 June By Investing.com
Profile
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. Wikipedia
About Cytokinetics, Inc.
CEORobert I. Blum | Robert I. Blum
Employees673
Founded1997
HeadquartersSouth San Francisco, ແຄລິຟໍເນຍ, ສະຫະລັດ
SectorBiotechnology
Websitecytokinetics.com
Analyst ratings
Based on 16 analysts giving stock ratings to CYTK in the past 3 months
Strong buy
Buy
14
Hold
2
Sell
0
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for CYTK in the last 3 months.
Highest
Current US$80,80
US$140,00 (+73,27%)
Average
US$104,20 (+28,96%)
Lowest
US$80,00 (-0,99%)
Analyst
Recommendation
Action
Price target
Projected
Date
Salim Syed
Mizuho Securities
Buy
Maintained
US$118,00
+46%
06/23/2026
Eric Joseph
Citi
Buy
Reiterated
US$99,00
+22,5%
06/16/2026
Maxwell Skor
Morgan Stanley
Buy
Maintained
US$103,00
+27,5%
06/16/2026
Jason Zemansky
Bank of America Securities
Hold
Maintained
US$83,00
+2,7%
06/16/2026
Serge Belanger
Needham
Buy
Maintained
US$102,00
+26,2%
06/16/2026
Tessa Romero
J.P. Morgan
Buy
Maintained
US$97,00
+20%
06/05/2026
Unknown Analyst
Citi
Buy
Initiated
US$99,00
+22,5%
05/19/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
US$140,00
+73,3%
05/12/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
US$105,00
+30%
05/07/2026
James Condulis
Stifel Nicolaus
Buy
Reiterated
US$108,00
+33,7%
05/06/2026
Unknown Analyst
Raymond James
Hold
Maintained
-
-
05/06/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
US$107,00
+32,4%
05/06/2026
Leonid Timashev
RBC Capital
Buy
Maintained
US$119,00
+47,3%
05/05/2026
Paul Choi
Goldman Sachs
Buy
Reiterated
US$101,00
+25%
05/05/2026
Srikripa Devarakonda
Truist Financial
Buy
Reiterated
US$106,00
+31,2%
05/06/2026
Emily Field
Barclays
Buy
Reiterated
US$95,00
+17,6%
04/06/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
US$80,00
-1%
04/01/2026
Ashwani Verma
UBS
Hold
Maintained
US$69,00
-14,6%
03/24/2026
Mayank Mamtani
B. Riley Securities
Buy
Reiterated
US$108,00
+33,7%
03/10/2026
Carter Gould
Cantor Fitzgerald
Buy
Maintained
-
-
02/25/2026
Jason Butler
Citizens JMP
Buy
Maintained
US$96,00
+18,8%
02/25/2026
Last report
5 ພ.ພ. 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
US$-1,67 / US$-1,65
-1,16%miss
Revenue / Est. (USD)
໑໙,໓໖ ລ້ານ / ໙,໐໘ ລ້ານ
+113,25%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
ມິ.ຖ. 2025
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
Revenue
66,77 ລ້ານ
1,94 ລ້ານ
17,76 ລ້ານ
19,36 ລ້ານ
Cost of goods sold
112,55 ລ້ານ
99,23 ລ້ານ
104,40 ລ້ານ
95,68 ລ້ານ
Cost of revenue
112,55 ລ້ານ
99,23 ລ້ານ
104,40 ລ້ານ
95,68 ລ້ານ
Research and development expenses
-
-
-
2,39 ລ້ານ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
65,72 ລ້ານ
69,46 ລ້ານ
91,72 ລ້ານ
104,90 ລ້ານ
Operating expense
65,72 ລ້ານ
69,46 ລ້ານ
91,72 ລ້ານ
107,29 ລ້ານ
Total operating expenses
178,28 ລ້ານ
168,69 ລ້ານ
196,12 ລ້ານ
202,97 ລ້ານ
Operating income
-111,51 ລ້ານ
-166,76 ລ້ານ
-178,37 ລ້ານ
-183,62 ລ້ານ
Other non operating income
-11,60 ລ້ານ
-2,10 ລ້ານ
14,20 ລ້ານ
-100,00 ພັນ
EBT including unusual items
-134,37 ລ້ານ
-306,18 ລ້ານ
-183,03 ລ້ານ
-206,03 ລ້ານ
EBT excluding unusual items
-134,37 ລ້ານ
-184,93 ລ້ານ
-183,03 ລ້ານ
-206,03 ລ້ານ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-134,37 ລ້ານ
-306,18 ລ້ານ
-183,03 ລ້ານ
-206,03 ລ້ານ
Net profit margin
-201,25%
-15.814,98%
-1.030,87%
-1.064,48%
Earnings per share
-1,12
-1,54
-1,50
-1,67
Interest and investment income
13,00 ລ້ານ
10,25 ລ້ານ
11,47 ລ້ານ
11,02 ລ້ານ
Interest expense
-24,26 ລ້ານ
-26,32 ລ້ານ
-30,34 ລ້ານ
-33,34 ລ້ານ
Net interest expenses
-11,26 ລ້ານ
-16,07 ລ້ານ
-18,86 ລ້ານ
-22,31 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
-109,22 ລ້ານ
-164,08 ລ້ານ
-175,50 ລ້ານ
-180,24 ລ້ານ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of CYTK
Explore what’s possible
Create portfolio
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer